Mitral valve replacement reduces mitral regurgitation, lowers HF hospitalization risk
Click Here to Manage Email Alerts
Among patients who underwent transcatheter mitral valve replacement for severe mitral regurgitation, 93% of those who survived to the 2-year follow-up had trace or no mitral regurgitation, researchers reported.
Although 2-year mortality was 39%, the rate was clinically acceptable due to advanced age at baseline, according to data presented at the virtual PCR e-Course.
“Historically, people who were ineligible for standard-of-care surgeries to treat their mitral or tricuspid regurgitation were limited to symptom management, which does not address the underlying condition,” Paul Sorajja, MD, the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital, said in a press release. “These devices treat extremely complex valve diseases that are debilitating and progress to very serious conditions when left untreated. The late-breaking data show significant and consistent reduction in regurgitation, allowing the heart valve to function as it is intended.”
The analysis of 2-year outcomes included 100 patients (mean age, 75 years; 69% men) who underwent transcatheter mitral valve replacement (Tendyne mitral valve, Abbott) between November 2014 and November 2017.
At 2 years, the rate of all-cause mortality was 39% and the rate of CV mortality was 34%, David W.M. Muller, MD, FRACP, FACC, associate professor and interventional cardiologist at St. Vincent’s Private Hospital and St. Vincent’s Clinic in Sydney, said during a presentation.
Among participants who were followed up, 93.2% had either no or only trace mitral regurgitation and the remaining 6.8% had a mitral regurgitation grade of 1+.
The annualized rate of HF hospitalizations decreased from the 6 months before to 6 months after mitral valve replacement (before, 1.3; after, 0.69; P = .01).
In addition, the participants’ average Kansas City Cardiomyopathy Questionnaire score improved by 19.1 points compared with baseline and 81.7% of the cohort was NYHA functional class I or II at 2 years compared with 66% being class III or IV at baseline.
“This study data supports the valve as a safe treatment option that provides symptom relief and improved quality of life for people with symptomatic mitral regurgitation who are not eligible for open-heart surgery or transcatheter mitral valve repair,” Abbott stated in the release.
Collapse
Muller DWM, et al. Mitral interventions – part 1. Presented at: PCR e-Course; June 25-27, 2020 (virtual meeting).
Click Here to Manage Email Alerts